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RECURRENT GESTATIONAL DIABETES MELLITUS: THE EFFECT OF A 
LIFESTYLE INTERVENTION  
AUDREY CROCKER 
ABSTRACT 
Gestational diabetes mellitus (GDM) is the most common complication of pregnancy that 
affects 1-14% of all pregnancies. If not properly managed, GDM can be a devastating 
disease, leading to birth complications such as shoulder dystocia and neonatal 
hypoglycemia. GDM has many long-term implications as well, such as increased risk of 
obesity and type 2 diabetes mellitus (T2DM) in both the mother and the offspring. 
Additionally, women with a history of GDM are at increased risk of recurrent GDM in a 
subsequent pregnancy and multiple episodes of GDM further increases a woman’s risk 
for these short and long-term consequences. For this reason, a diagnosis of GDM 
provides an opportunity to target GDM and T2DM risk factors to prevent recurrence of 
GDM and halt the diabetes disease course. Research has shown that diet and physical 
activity interventions provided after a pregnancy complicated by GDM can delay or 
prevent the onset of T2DM yet literature on prevention of recurrent GDM is lacking. 
This thesis will propose a new intervention applied to the inter-pregnancy interval 
(IPI), designed to reduce incidence of recurrent GDM. The study will examine the effect 
of a diet and physical activity intervention for women with a recent pregnancy 
complicated by GDM on recurrence in a subsequent pregnancy and weight gain in the 
IPI. We hypothesize that our intervention will reduce incidence of GDM recurrence 
compared to the control group and that women in the intervention group will lose more 
  vi 
weight compared to women in the control group. The results of this study will provide a 
background for further study on the prevention of GDM recurrence with the hope that 
prevention of recurrent GDM will prevent the short and long-term sequela of GDM. 
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INTRODUCTION 
Background 
As one of the most common complications of pregnancy in the United States, the 
diagnosis, management, and prevention of gestational diabetes mellitus (GDM) is a 
priority for affected individuals, healthcare providers and the healthcare system in the 
United States. The prevalence of GDM varies between 1-14% depending on the 
population studied and the diagnostic criteria used making it the most common 
complication of pregnancy in the United States.1  
GDM refers to any degree of glucose intolerance with the onset or first 
recognition during pregnancy and is a result of the acquired insulin resistance of 
pregnancy paired with underlying ß-cell dysfunction in the pancreas.2 In these women, 
the pancreas is unable to secrete adequate amounts of insulin to maintain euglycemia 
during pregnancy, leading to hyperglycemia and, thus, GDM.2 There are many long and 
short-term consequences associated with GDM. These include shoulder dystocia, 
neonatal hypoglycemia and an elevated risk to both the mother and fetus of becoming 
overweight or obese and of developing type 2 diabetes mellitus (T2DM).3,4,5,  
The prevalence of GDM tends to mirror the prevalence of T2DM in a given 
population due to overlapping pathophysiology and risk factors. Therefore, due to 
increased prevalence of risk factors such as overweight and obesity, rates of T2DM as 
well as rates of GDM are increasing in the United States. A diagnosis of GDM is an early 
indicator of an increased risk of T2DM, providing an early opportunity to target risk 
factors to prevent the short-term consequences of a recurrent episode of GDM and the 
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long-term consequences of recurrent GDM such as increased risk of T2DM.6,7,8  
 Due to the significant adverse consequences of GDM, adequate screening and 
diagnosis is critical. While there are many screening and diagnostic criteria, the 
International Association of Diabetes in Pregnancy Study Groups (IADPSG) and the 
American Diabetes Association (ADA) maintain the most accepted guidelines. The 
IADPSG recommends screening all women at the first prenatal visit while the ADA only 
recommends screening with risk factors present at the first prenatal visit.3,9  
 First line treatment of GDM includes diet and exercise. Second line treatment 
includes pharmacologic treatment with oral hypoglycemic agents such as metformin and 
glyburide or insulin therapy.3 Management of GDM using any of these methods is reliant 
on home glucose monitoring.10  
 Understanding the pathophysiology, prevalence, and risk factors for GDM are 
integral to prevention of GDM. Common risk factors for GDM include older age, 
overweight or obesity, high parity, excessive weight gain in pregnancy, and a prior 
history of GDM.2,11, 12 By targeting the modifiable risk factors, the diabetes disease 
course may be delayed or prevented.  
 
Statement of the Problem 
Women with a history of GDM are at increased risk of recurrent GDM.12 With each 
episode of GDM, a woman’s risk of adverse short term outcomes and of T2DM 
increases.13,14,15 Therefore, preventing recurrence of GDM by targeting risk factors in the 
inter-pregnancy interval (IPI), the time between two consecutive live births minus the 
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second infant’s gestational age, can potentially decrease these adverse consequences.16 
There are modifiable and non-modifiable risk factors in the IPI that affect a woman’s risk 
of recurrent GDM. Modifiable risk factors include the length of the IPI and weight gain 
during the IPI.12 Existing research examining the effect of the length of the IPI on 
incidence of GDM recurrence is contradictory, however studies have consistently shown 
that weight gain during the IPI increases a woman’s risk of recurrent GDM.17,18 
Therefore, weight gain during the IPI is a risk factor that may be effectively targeted in 
order to prevent GDM recurrence.  
Previous studies have shown that lifestyle interventions targeting weight loss 
during the subsequent pregnancy after a GDM index pregnancy decrease incidence of 
recurrent GDM.19 Additionally, the literature demonstrates that diet and exercise 
interventions decrease incidence of T2DM after a GDM pregnancy. However, there are 
no studies that have examined a lifestyle intervention targeting weight loss during the IPI.  
Because diet and exercise interventions have been shown to be effective under 
other circumstances, this study targets weight gain between pregnancies with a diet and 
exercise intervention after a pregnancy complicated by GDM. The recurrence of GDM 
will be examined in order to determine if lifestyle intervention decreases recurrence of 
GDM. The prevention of recurrent GDM is important in preventing adverse outcomes of 
a GDM pregnancy and ultimately decreasing the risk of developing T2DM. 
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Hypothesis 
A diet and exercise intervention provided to overweight women for one year immediately 
following a pregnancy complicated by GDM will decrease the incidence of recurrent 
GDM in a subsequent pregnancy.  
 
Objectives and specific aims 
Due to the immense health implications of GDM, prevention of recurrent GDM is 
integral in improving health outcomes for women with a history of GDM. A diagnosis of 
GDM offers a unique opportunity to identify women at high risk for recurrent GDM or at 
high risk for future T2DM. Therefore, interventions to modify risk factors are integral in 
modifying the disease course. This study will seek to provide a lifestyle intervention in 
the IPI in overweight women with a recent pregnancy complicated by GDM in order to 
prevent recurrence of GDM in a subsequent pregnancy. There are three specific aims of 
this study: 
• To determine if incidence of recurrent GDM can be decreased with a lifestyle 
intervention in overweight women. 
• To determine the effectiveness of a lifestyle intervention on weight loss in the IPI.  
• To determine if weight lost or weight gained during the IPI is associated with 
recurrent GDM. 
 
 5 
REVIEW OF THE LITERATURE 
Overview of gestational diabetes mellitus 
GDM is defined as any degree of glucose intolerance with the onset or first recognition 
during pregnancy.20  This definition of GDM includes women who may have had 
unrecognized or undiagnosed glucose intolerance before their pregnancy and those with 
an onset during pregnancy which continued after pregnancy.1 GDM is the most common 
complication of pregnancy in the United States with a prevalence between 1-14% 
depending on the population studied and the diagnostic criteria used.1  
The implications of gestational diabetes are immense with short and long-term 
adverse effects for both the mother and the fetus. Short term consequences for the fetus 
include fetal macrosomia (birthweight > 4000g) and neonatal hypoglycemia.5,21 Because 
glucose easily crosses the placenta, maternal hyperglycemia leads directly to fetal 
hyperglycemia. The pancreas of the fetus then responds by increasing its own insulin 
production and release. The resulting fetal hyperinsulinemia causes the majority of 
adverse fetal consequences of GDM.3 Fetal macrosomia is a direct result of GDM. The 
hyperinsulinemic state of the fetus promotes excessive and disproportionate growth 
including excessive subcutaneous fat and broad shoulders, leading to should dystocia,4 a 
complication of labor where the anterior shoulder of the infant is unable to pass below the 
pubic symphysis after delivery of the head. 4,22 The delivery of an infant with shoulder 
dystocia can often result in birth trauma, such as clavicle fracture or nerve injury to the 
brachial plexus, which can lead to long term complications such as Erb’s palsy.3  
Hypoglycemia in the neonatal period is another adverse effect of fetal 
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hyperinsulinemia. After birth, the infant is no longer exposed to the maternal source of 
glucose yet still has elevated circulating insulin levels, leading to hypoglycemia in the 
early neonatal period.3,5 Neonatal hypoglycemia must be addressed rapidly to minimize 
the risk of serious adverse consequences such as seizures, brain injury, and long term 
neurodevelopmental impairment.3,23 Other adverse outcomes include hyperbilirubinemia 
and hypocalcemia, both of which may require close monitoring in the NICU.3 
Additionally, the hyperglycemic intrauterine environment predisposes the fetus to early 
onset diabetes, in adolescence or early adulthood, even in populations with a relatively 
low incidence of T2DM.24,25 T2DM is a metabolic disease that is characterized by 
dysfunction in insulin secretion, insulin action, or both. This dysfunction leads to chronic 
insulin resistance and resulting chronic hyperglycemia. Typically, T2DM has an onset in 
adulthood however, with increasing prevalence of risk factors, early onset T2DM is 
becoming more common.26 
The maternal consequences of GDM include preeclampsia and cesarean section in 
the short term and increased risk of T2DM in the long term. If GDM remains untreated, 
mothers are at a higher risk of preeclampsia and cesarean section.27,5 While GDM itself is 
not an indication for cesarean section, the complications associated with GDM, such as 
preeclampsia and macrosomia, may be an indication for cesarean section (c-section). If 
the mother is diagnosed with preeclampsia that necessitates early delivery and the 
mother’s cervix has not sufficiently ripened for delivery, a c-section is indicated. C-
section is indicated for macrosomia if the estimated fetal weight exceeds 4500 g in order 
to prevent shoulder dystocia and birth trauma during vaginal delivery.3  
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The pathophysiology of GDM originates from normal acquired insulin resistance 
of pregnancy. Throughout pregnancy, the placenta stimulates changes in maternal insulin 
resistance and metabolism of carbohydrates, lipids, and amino acids in order to provide a 
continuous and adequate supply of nutrients to the fetus for growth.2 Insulin resistance is 
achieved with pregnancy-induced factors, such as placental growth hormone and tumor 
necrosis factor-alpha which stimulate a reduction in peripheral insulin uptake at the level 
of the skeletal muscle, a common site for whole-body glucose storage.28 This leads to the 
acquired insulin resistance of late pregnancy and a more robust glucose supply to the 
fetus. Insulin resistance increases until the 24th week of pregnancy when elevated 
maternal glucose levels plateau and are maintained until delivery. Typically, the maternal 
pancreas is able to increase secretion of insulin to keep up with increased insulin 
resistance and maintain euglycemia.2 However, in some cases the pancreas is unable to 
secrete adequate amounts of insulin, leading to maternal hyperglycemia and GDM.2 The 
acquired insulin resistance of pregnancy typically returns to normal soon after delivery 
and resolves completely within one year.28 All women with GDM require post-partum 
glucose testing to determine if blood glucose levels have returned to baseline or if the 
patient has persistent impaired glucose tolerance or T2DM.29 
In order to manage the potential adverse outcomes of GDM, a mother’s blood 
glucose must be controlled throughout her pregnancy. In all women with GDM, self-
monitoring of blood glucose is recommended with the following goals based on 
American Obstetrics and Gynecology Guidelines (ACOG) — Fasting value: <95 mg/dL, 
1 hour postprandial: <120-130 mg/dL, 2 hour postprandial: <120 mg/dL.10 When a 
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woman presents with GDM, first line treatment to achieve euglycemia includes diet and 
exercise. Ideally, patients will meet with registered dieticians who can help patients to 
control blood glucose levels and manage appropriate weight gain during pregnancy.3 If 
blood glucose levels remain uncontrolled with diet and exercise, pharmacologic 
treatment, such as insulin or oral hypoglycemic agents are used. Although oral 
hypoglycemic agents such as glyburide and metformin are commonly used as first-line 
pharmacologic therapy, they have not been approved by the U.S. Food and Drug 
Administration for GDM.3,30 Glyburide works by stimulating insulin production and 
release from the pancreas and is effective in lowering HgbA1c concentrations, decreasing 
rates of macrosomia, and decreasing rates of neonatal hypoglycemia.3 Metformin is an 
insulin sensitizer in the liver and in the periphery and has been shown to be effective in 
decreasing adverse pregnancy outcomes.3 GDM can also be effectively managed with a 
combination of intermediate acting insulin preparations, such as Neutral Protamine 
Hagedorn (NPH), and short-acting insulin analogs, such as Insulin Lispro and Insulin 
Aspart.3 
There are multiple proposed screening and diagnostic guidelines for GDM 
globally, leading to variable rates of GDM based on the diagnostic criteria used.31 
O’Sullivan and Mahan developed the first screening and diagnostic guidelines for GDM 
in the 1960s, based on a 3-hour 100-gram oral glucose tolerance test (OGTT).32 The 
thresholds developed from the Sullivan criteria were based on the blood glucose 
thresholds that predicted subsequent diabetes in the mother after her pregnancy.32 These 
thresholds were based on venous blood samples and were subsequently altered by the 
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National Diabetes Data Group (NDDG) and Carpenter and Coustan to account for 
laboratories’ use of plasma measurements compared to whole blood measurements.3 The 
American Diabetes Association (ADA) endorsed the Carpenter and Coustan (C&C) 
criteria due to improved accuracy in determining glucose levels from plasma. The C&C 
criteria then became the recommended diagnostic threshold validated by ACOG. Because 
of the known adverse perinatal outcomes of GDM, it became clear that diagnostic criteria 
must be able to predict adverse pregnancy outcomes. The Hyperglycemia and Adverse 
Pregnancy Outcomes (HAPO) study showed a direct relationship between the GTT 
values at 24-32 weeks gestation and adverse pregnancy outcomes, particularly fetal 
hypoglycemia and macrosomia.5 Based on data from the HAPO study, the International 
Association of Diabetes in Pregnancy Study Groups (IADPSG) developed thresholds for 
the use of a 75-g 2-h OGTT for diagnosis (Table 1). Due to the lower threshold glucose 
values, the IADPSG criteria increased the prevalence of GDM nearly two-fold.33 The 
IADPSG recommends screening all women at the first prenatal visit with a fasting 
plasma glucose or a random plasma glucose while the ADA only recommends screening 
women with risk factors present at the first prenatal visit.3 In the United States, ACOG 
recommends women at risk for GDM typically undergo testing as soon as possible in 
pregnancy, while all other women are universally screened at 24-28 weeks gestation. 
ACOG recommends a two-step screening approach involving a 50-g glucose challenge 
test followed by a 100-g 3-h OGTT if results of the initial screen are abnormal. 26,30 Most 
other countries do not universally screen for GDM and recommend a one-step approach 
with 75-g 2-h OGTT, fasting plasma glucose, or random plasma glucose.26,30 Presently, 
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both the IADPSG and the ADA recommend the 75-g, 2-h OGTT for GDM at 24-28 
weeks gestation in those who have not already been diagnosed with GDM.3, 9 The 
commonly used screening and diagnostic guidelines for GDM among different groups are 
presented in Table 1.  
Table 1: Commonly used screening and diagnostic criteria for GDM3 
Time of glucose 
measurement 
Original values 
(O’ Sullivan and 
Mahan)32, 
venous whole 
blood 
 
NDDG 
modification 
(NDDG)21, 
plasma 
 
C&C 
modification 
(Carpenter 
and Coustan)34 
– ADA criteria 
IADPSG33 
2010 
 
WHO31 2013 
 
Approach 100-g OGTT 100-g OGTT 100-g OGTT 75-g OGTT 75-g OGTT 
Number of 
abnormal values 
required for 
diagnosis 
2 2 2 1 1 
Fasting 
mmol/L (mg/dL) 
90 (5.00) 105 (5.83) 95 (5.27) 92 (5.1) 126 (≥ 7.0) 
1 h 
mmol/L (mg/dL) 
165 (9.16) 190 (10.55) 180 (9.99) 180 (10.0) - 
2 h 
mmol/L (mg/dL) 
143 (7.94) 165 (9.16) 155 (8.60) 153 (8.5) 200 (≥ 11.1) 
3 h 
mmol/L (mg/dL) 
127 (7.05) 145 (8.05) 140 (7.77) - - 
OGTT: oral glucose tolerance test 
Adapted from Alfadhli et al31 and Coustan et al3 
 
 When screening a woman for GDM, risk factors for GDM must be closely 
examined. Risk factors for GDM include older age, overweight or obesity, high parity, 
excessive weight gain in pregnancy, short stature, polycystic ovarian syndrome, history 
of diabetes mellitus in first degree relatives, macrosomia in previous and/or index 
pregnancy, and a past history of poor pregnancy outcomes.2,11 Because the ADA 
recommends screening at the first antepartum visit for women with a risk of developing 
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GDM, the patient must be identified as high, average, or low risk based on her risk 
factors and screened accordingly as detailed in Table 2.35  
Table 2: Clinical risk assessment and screening for GDM35 
Risk category Clinical characteristics Recommended screening 
High risk (presence of any 
is sufficient) 
-Marked obesity 
-Diabetes in first degree 
relative (s) 
-Personal history of 
glucose intolerance 
-Prior delivery of 
macrosomic infant 
-Current glycosuria 
Blood glucose screening at 
initial antepartum visit or 
as soon as possible 
thereafter; repeat at 24-28 
weeks if not already 
diagnosed with GDM by 
that time 
Average risk Fits neither low- nor high-
risk profile 
Blood glucose screening 
between 24-28 week 
gestation 
Low risk (all required) -Age <25 
-Low-risk ethnicity 
-No diabetes in first-degree 
relatives 
-Normal prepregnancy 
weight and pregnancy 
weight gain 
-No personal history of 
abnormal glucose levels 
-No prior poor obstetrical 
outcomes 
Blood glucose screening 
not required 
Adapted from Buchanan et al35 based on recommendations of the American Diabetes Associations 
 
Proper screening and diagnostic criteria are important to avert the societal and 
economic costs of GDM. As discussed above, women with GDM are at an elevated risk 
of developing T2DM. According to England et al,36 T2DM, a major sequela of GDM, is 
emerging as a leading cause of death and disability in the United States.37 Up to 70% of 
women develop T2DM within the first 10 years after a GDM pregnancy.7 People with 
T2DM are at increased risk for developing renal, cardiovascular, and retinal diseases 
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which poses a significant economic burden, $91.8 billion per year in the United States.6 
For this reason, prevention of T2DM is critical in improving individual and societal 
health. Because GDM has been shown to increase risk of developing T2DM, a diagnosis 
of GDM can be used as an early identifiable risk factor for T2DM and an early 
opportunity to alter the diabetes disease course. Thus, an understanding of the 
pathophysiology, prevalence, and risk factors for developing T2DM after GDM is 
important in order to develop interventions that can prevent the GDM to T2DM disease 
course.   
 
Gestational diabetes mellitus is a risk factor for type 2 diabetes mellitus 
GDM increases a woman’s risk of developing T2DM later in life due to shared 
risk factors and pathophysiology. A personal history of GDM has been found to be the 
most significant risk factor for developing T2DM and women with a history of GDM 
have a 7 fold risk of developing T2DM.6,8 A meta-analysis done by Kim et al.7 reported 
the risk of developing T2DM after GDM increases sharply within the first 5 years 
postpartum and that women with higher glucose levels during pregnancy were at 
increased risk for developing T2DM. Additionally, GDM and T2DM share many of the 
same risk factors including family history of diabetes, increased age, increased BMI, and 
Asian and black ethnicity.7 Other risk factors for the development of T2DM after GDM 
include an elevated pre-pregnancy BMI, insulin requirement during pregnancy, and 
diagnosis of GDM early in pregnancy.38,39,40  
 GDM and T2DM share two main pathophysiological defects: target cell insulin 
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resistance and insufficient secretion of insulin from the pancreatic beta cells.35 Acquired 
insulin resistance of pregnancy typically occurs by the 24th week of gestation as a method 
to elevate circulating blood glucose levels and increase glucose supply to the fetus. 
Typically, a mother’s pancreatic beta cells are able to increase insulin production and 
secretion to maintain euglycemia. However, when the mother’s beta cells are unable to 
produce and secrete sufficient insulin to maintain euglycemia during acquired insulin 
resistance, maternal hyperglycemia and GDM occurs.2 Insufficient beta cell function 
during pregnancy stems from maternal chronic insulin resistance. Thus, women with 
GDM typically exhibit two form of insulin resistance: the normal acquired insulin 
resistance of pregnancy in addition to an underlying chronic insulin resistance.41 Chronic 
insulin resistance is associated with  risk factors such as overweight, obesity, excessive 
weight gain during pregnancy, PCOS, IGT, or metabolic syndrome.2 Women with 
chronic insulin resistance tend to become insulin resistant earlier in pregnancy and are 
more likely to be remain glucose intolerant post-partum.41 With the onset of acquired 
insulin resistance of pregnancy, beta cells, already stressed from chronic insulin 
resistance, are unable to fulfill the need for increased insulin secretion.42 The additional 
secretory demands put on beta cells during pregnancy further depletes the body’s beta 
cell reserve, predisposing women with a history of GDM to developing T2DM in the 
future.42  
The risk of developing T2DM after GDM is increasing, reflecting an increasing 
prevalence of T2DM in women globally.43 The incidence of overweight and obesity in 
women of childbearing age is also increasing, putting more women at risk for developing 
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GDM. Rates of GDM tend to mirror rates of T2DM in a given population; as the 
prevalence of common risk factors, such as obesity, begin to increase so does the 
prevalence of GDM and T2DM. Similarly, metabolic syndrome is an indicator of future 
risk of T2DM. A study by Retnakaran et al.44 found that women with glucose intolerance 
in pregnancy have an increased risk of developing metabolic syndrome postpartum.44 
Metabolic syndrome is characterized by central obesity, dysglycemia, hypertension, 
hypertriglyceridemia, and low high-density lipoprotein cholesterol and increases lifetime 
risk for T2DM and cardiovascular disease.45 Therefore, targeting characteristics of 
metabolic syndrome after GDM, such as obesity, may resolve the metabolic changes after 
pregnancy, delaying or preventing the onset of T2DM.44 
 
Gestational diabetes mellitus recurrence and the inter-pregnancy interval 
A recent meta-analysis by Schwartz et al.12 reported a pooled GDM recurrence rate of 
48%.12 Schwartz et al. identified risk factors for recurrence of GDM. Multiparous women 
had a higher recurrence rate (73%) compared to primiparous women (40%). Additionally, 
ethnicity was a risk factor for GDM recurrence; non-Hispanic whites had a rate of 38% 
while all other ethnicities had a recurrence rate of 56% Although the meta-analysis found 
ethnicity to be a significant risk factor, family history of diabetes was not. Thus, the 
difference in recurrence rate among ethnic groups may not originate from genetic factors 
but most likely originates from non-genetic factors, such as socioeconomic status, 
nutrition, lifestyle, and education status. Other risk factors include age, insulin use in 
previous pregnancy, large for gestational age infant, and hypertension in the first or 
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second pregnancy.12,15 Additionally, the risk of recurrent GDM increases with each 
episode of GDM.46 As a woman’s beta cells are stressed to produce adequate insulin to 
maintain euglycemia, cellular function is further depleted. Thus, insulin resistance during 
a subsequent pregnancy after GDM increases risk of recurrent GDM because of the 
previously impaired beta cell function.12  
 The literature about the effect of a subsequent pregnancy after GDM on the risk of 
T2DM is contradictory. A study by Peters et al.13 reported that an episode of insulin 
resistance in a subsequent pregnancy, regardless of whether it was complicated by GDM, 
progresses beta cell dysfunction and may increase risk of T2DM.13 However, recent 
studies have reported that recurrent GDM may increase a lifetime risk of T2DM 2-fold 
while a subsequent pregnancy without GDM does not increase risk.14,15 Despite the 
acquired insulin resistance of pregnancy, a normal pregnancy may not contribute to the 
depletion of beta cell reserves to the same extent as a GDM pregnancy.14 In fact, a 
subsequent pregnancy without GDM may be indicative of a reduced risk of developing 
T2DM; in a previously identified high-risk population, the outcomes of a subsequent 
pregnancy can offer an updated risk assessment of future T2DM. 44 Because studies have 
shown that a subsequent pregnancy that is not complicated by GDM may be protective 
against T2DM, prevention of recurrent GDM is key in reducing risk of T2DM.  
 Therefore, the time between pregnancies, or the inter-pregnancy interval (IPI), 
may be an integral time to target modifiable risk factors in the prevention of recurrent 
GDM. Modifiable risk factors of GDM recurrence include the length of the IPI and 
weight gain between pregnancies.12 
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The association between the length of the IPI and risk of GDM recurrence is 
unclear. Two studies have been completed that found that a shorter IPI is a risk factor for 
recurrent GDM17,47 and three studies found that a longer IPI is a risk factor for recurrent 
GDM.16,47,48 With shorter IPIs, women who become pregnant soon after a pregnancy 
complicated by GDM are less likely to have lost excess weight gained during their 
pregnancy which could increase their risk of GDM.17 This suggests that rather than length 
of IPI, risk of GDM may be dependent on weight gain or loss between pregnancies. The 
studies supporting short IPI as a risk factor were limited by small sample sizes (N=78 for 
Major et al. and N=32 for Nohira et al.). Additionally, the study by Nohira et al. did not 
include multivariate analysis and included only women with diet-treated GDM. The 
studies supporting longer IPI as a risk factor16,49,48 include large sample sizes and 
multivariate analysis to account for all variables.  
Evidence on the relationship between weight gain between pregnancies and GDM 
recurrence is stronger. Previous studies have identified weight gain between pregnancies 
as a risk factor with a weight gain greater than or equal to 15 pounds during the IPI 
associated with recurrent GDM.17 A study by Ehrlich et al., similarily, found that women 
who increase their BMI units between pregnancies are at a higher risk for recurrent 
GDM. 50 A reduction in BMI units between pregnancies significantly reduced risk in 
women who were overweight or obese while BMI gains between pregnancies increased 
risk for women of normal weight.18 These results demonstrate the important role of 
postpartum weight retention and weight gain in the risk of recurrent GDM.  
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Because GDM recurrence is a predictor of T2DM, interventions that decrease 
recurrence rates may eventually delay or prevent the onset of T2DM.12 Literature on the 
optimal length of the IPI is contradictory and, thus, future observational studies will be 
needed to understand the IPI length as a risk factor. However, gains in BMI units 
between pregnancies have been shown to increase recurrence of GDM, indicating that 
this risk factor may be successfully targeted with interventions to reduce the incidence of 
recurrent GDM. 
 
Existing research on prevention of GDM recurrence 
The IPI is an integral time for lifestyle or pharmacological interventions that can 
potentially alter the diabetes disease course by either preventing recurrence of GDM or 
preventing or delaying the onset of T2DM. While there are few studies that have 
examined prevention of recurrent GDM, many studies have examined interventions to 
prevent T2DM after a diagnosis of GDM. Many of these interventions can be feasibly 
applied to the IPI to reduce incidence of recurrent GDM. Three different types of 
interventions have been studied to date: lifestyle (diet and physical activity), 
pharmacologic, and breastfeeding.   
 A study by Hu et al.51 examined the effect of dietary intervention in women with 
a history of GDM. The two-year long intervention involved eight meetings with study 
dietitians: six meetings in person during the first year and two telephone meetings during 
the second year. Participants who received the intervention lost more weight within the 
first year than those in the control groups. Women demonstrated healthier behaviors 
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including increased leisure time physical activity and dietary fiber intake with decreased 
sedentary time and fat consumption. Women in the intervention group showed decreased 
BMI, waist circumference, and plasma insulin levels. 
The Diabetes Prevention Program (DPP) Research Group demonstrated that an 
intensive lifestyle-modification program significantly decreased the risk of developing 
T2DM in people with impaired glucose tolerance. The research group reported a 58% 
reduction in the incidence of T2DM and a mean weight loss of 5.6 kg among the lifestyle 
modification group compared to placebo.52 In a follow-up study, the effect of a lifestyle 
intervention on development of T2DM was examined in women with a history of GDM. 
350 women from the DPP self-reported a history of GDM and were compared to1416 
women in the study who reported a prior live birth but no history of GDM. Women were 
assigned to a life-style intervention group, metformin group, or placebo group. Women 
with a history of GDM had a 53.4% reduced risk of developing T2DM compared to 
placebo after the intensive life-style intervention and a reduction of 50.4% after the 
metformin treatment.53 In a study done on women with a history a GDM who were 
warned of the high risk of T2DM and informed of the importance of healthy lifestyle 
modification, few women changed their lifestyle or lost weight after their pregnancy; 
33% of the women gained weight after pregnancy and only 18% lost at least 5 kg.54 The 
difference in outcomes between these two studies show that a more intensive, scheduled 
lifestyle intervention is more effective compared to counseling. 
While the studies by Hu et al.51 and Ratner et al.53 examined lifestyle 
interventions in women with a history of GDM, they did not examine women in the 
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postpartum period. A study by O’ Toole et al.55 enrolled overweight, postpartum women 
into an intervention group to receive diet and activity recommendations, participate in 
group sessions, and record progress in a diet and activity journal. The intervention group 
lost significantly more weight (7.3 kg) within 1 year postpartum compared to the control 
group (1.4 kg). Although this study did not measure glucose levels, it shows that 
structured diet and exercise interventions in the postpartum period are effective in 
modifying risk factors for GDM recurrence and T2DM.  
 Breastfeeding has been associated with lower blood glucose levels postpartum as 
well as a reduced incidence of T2DM in women with a history of GDM.56 A study by 
Stuebe et al.57 showed that with each year of lifetime lactation, there was a 15% 
reduction in the risk of T2DM. A review by Keller et al.58 examined the relationship 
between diet and exercise interventions in women who are breastfeeding and weight loss 
in the postpartum period. The review revealed that women receiving the diet and physical 
activity interventions lost more weight while breastfeeding than those who were not 
breastfeeding. This shows that a combination of lifestyle interventions and breastfeeding 
can help high-risk women manage weight postpartum to prevent or delay T2DM. 
 Randomized clinical trials have been completed studying pharmacologic 
interventions to decrease risk of T2DM after GDM. Drugs that have been studied include 
troglitazone and pioglitazone which decrease insulin resistance and metformin which 
decreases hepatic glucose production and improves insulin sensitivity. The Troglitazone 
in the Prevention of Diabetes (TRIPOD) study59 performed a randomized clinical trial 
using troglitazone or placebo in obese Hispanic women with a history of GDM. The 
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study found a 55% decrease in the incidence of T2DM, which was explained by 
preservation of the pancreatic ß-cells during the intervention period. Women who did not 
develop T2DM during the TRIPOD study were enrolled into  the Pioglitazone in 
Prevention of Diabetes (PIPOD) study60 and received pioglitazone or placebo for 3 years. 
Results showed a significantly lower incidence of T2DM in the intervention group (4.6% 
yearly incidence rate) compared to placebo group (12.1% yearly incidence rate). 
Additionally, the DPP study showed a 50% reduction in T2DM incidence after treatment 
with metformin.53 Although troglitzone, pioglitazone, and metformin showed significant 
reduction in T2DM incidence, none are currently approved by the FDA for prevention of 
T2DM.  
While the above trials discuss prevention of T2DM, a trial by Koivusalo et al. 
administered a lifestyle intervention to prevent recurrent GDM. This trial assessed the 
effect of a moderate diet and exercise intervention on the incidence of GDM in pregnant 
women with either a history of GDM or a BMI >30 kg/m2. 19 The intervention included 3 
visits with a study nurse and one group visit to the group dietitian during pregnancy. 
There was a 39% decrease in incidence of GDM among these high-risk pregnant women 
despite a minority of women in the intervention groups reaching physical activity goals 
and only minor differences in weight gain between the intervention and control groups 
(7.6 kg vs. 7.7 kg, respectively). Thus, only small changes in lifestyle during pregnancy 
are necessary to prevent GDM. This lifestyle intervention is significant because it is 
generalizable and can be implemented by primary care providers.19  
 The above studies show that interventions exist that are effective in preventing or 
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delaying onset of T2DM in high-risk women. However, the efficacy of these 
interventions applied to the interconception period in preventing GDM recurrence is 
unclear. The Koisulavo et al. study showed a reduction in recurrent GDM, however, the 
intervention was only applied after conception of a woman’s subsequent pregnancy. 
Literature on management of risk factors during the IPI and interventions during the IPI 
to reduce recurrence of GDM is lacking. However, literature in this area is needed 
because, as discussed above, recurrence of GDM is a risk factor for developing T2DM. 
As a first diagnosis of GDM is an early identifier of those at higher risk for T2DM, 
women with GDM are an easily targeted group at high risk for T2DM. It is therefore 
important to manage risk factors early in order to prevent recurrent GDM. In this study, 
investigators will test a lifestyle intervention applied after an index pregnancy 
complicated by GDM in an effort to reduce the incidence of recurrent GDM.  
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METHODS 
Study design 
This is a randomized controlled intervention trial targeting women with GDM. 
Participants will be overweight women with an index pregnancy complicated by GDM. 
The goal of this study will be to implement a lifestyle intervention that allows women to 
lose BMI units during the IPI with the goal of lowering the incidence of recurrent GDM. 
Participants will be recruited to the study by their participating obstetrician during 
their index pregnancy. All enrolled women will be planning a subsequent pregnancy 
within the next 2 years and are willing to use contraception during the study period. 
Women will be randomized into a life-style intervention group or a control group. The 
lifestyle intervention group will receive diet and physical activity counseling and will 
keep a weekly diet and physical activity journal. Physical activity goals will include 150 
minutes of leisure time physical activity per week and improved diet (within 11 different 
diet components) with the goal of losing 5% of their pre-pregnancy weight. The 
intervention will be given for 1 year and all women will be followed through their second 
pregnancy. The goal of this study is to determine whether a life-style intervention for 
overweight women in the interconception period after a pregnancy complicated by GDM 
will decrease the incidence of GDM in a subsequent pregnancy.  
Study population and sampling 
Participants will be overweight, primiparous women enrolled after a pregnancy 
complicated by GDM. After delivery, eligible women will receive their 6-week 
postpartum glucose testing. Women with normal results will be enrolled in the study, 
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randomized, and a lifestyle intervention will be provided for one year. Women will be 
planning a second pregnancy within the next 1-2 years. 
Study sample: Eligible participants will be overweight (BMI between25-30 
kg/m2), primiparous, planning a pregnancy within the next 1-5 years, willing to use birth 
control for the intervention period, have a negative pregnancy test at enrollment, and be 
English or Spanish speaking (Table 3). Researchers will restrict enrollment to an 
overweight population of women in order to restrict heterogeneity of the sample. 
Overweight women make up a large portion of the women who develop GDM and are at 
risk for developing T2DM. Additionally, a prior study by Ehrlich et al.50 showed that 
women who were previously overweight and lost BMI units before the second pregnancy 
had a lower incidence of recurrent GDM. Therefore, overweight women may most 
benefit from a life-style intervention. Women will only be enrolled if their first pregnancy 
was complicated by GDM. Because parity is a risk factor for GDM, isolating primiparous 
women will remove confounding factors. Because women over 35 are at higher risk for 
GDM and T2DM outside of pregnancy, enrolled women will be less than 35. Women 
will only be enrolled in the study if the postpartum OGTT is normal in order to isolate 
glucose intolerance during pregnancy as a risk factor for recurrent GDM. Investigators 
will include breastfeeding and non-breastfeeding mothers in order to maintain an 
adequate sample size.  
Exclusion criteria: Exclusion criteria include women who are pregnant at 
enrollment or planning to become pregnant during the intervention period, women with 
type 1 or type 2 diabetes, women who use of any medication that influences glucose 
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metabolism such as continuous corticosteroids or metformin, and women with substance 
abuse or with physical disability (Table 3). Additionally, women will be excluded if they 
have a history of acute or chronic pancreatitis, obesity induced by drug treatment, MDD 
or suicide attempt, or uncontrolled hypertension, if they have used any approved weight 
loss pharmacotherapy or have a history of surgical treatment of obesity, or if they are 
unable to give written or informed consent.  
Table 3: Project inclusion and exclusion criteria 
Inclusion Criteria Exclusion Criteria 
• Overweight (BMI 25-30 kg/m2) 
• Primiparous 
• Prior history of GDM (first 
documented episode of glucose 
intolerance during first pregnancy) 
• Age 18-35 years old 
• Normal 6 week postpartum OGTT 
after pregnancy with GDM 
• Planning a pregnancy within the 
next 1-2 years 
• Willing to use birth control for 
intervention period 
• Negative pregnancy test at 
enrollment 
• English or Spanish speaking 
• Pregnant at enrollment or planning 
to become pregnant during 
intervention period 
• Diagnosis of type 1 or type 2 
diabetes mellitus 
• Use of medication that influences 
glucose metabolism: e.g. 
corticosteroids or metformin 
• Substance use disorder 
• Physical disability 
• Medical history of: acute or 
chronic pancreatitis, obesity 
induced by drug treatment, MDD 
or suicide attempt, or uncontrolled 
hypertension 
• History of weight loss 
pharmacotherapy 
• History of surgical treatment of 
obesity 
• Unable to give written or informed 
consent 
 
Randomization: Randomization will be done by a study nurse by dispensing the 
next sequentially numbered code envelope containing the intervention arm to be assigned 
to the participant. The intervention and control arms will be balanced equally. 
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Size of study population and power calculation: Based on data on GDM 
recurrence, the pooled GDM recurrence rate is 48%.12 Because the women participating 
in this study are all primiparous, the estimated recurrence rate for this cohort will be 
lower, due to previous findings that recurrence is lower in primiparous vs multiparous 
women. Thus, the estimated recurrence rate used will be 40% as reported by Schwartz et 
al.12 A 40% risk reduction will be used based a study by Koivusalo et al. of women who 
participated in a lifestyle intervention during a subsequent pregnancy after a GDM 
pregnancy.19 Using an alpha of 0.05, power of 80%, probability of control exposure is 
40% and probability of exposure in the intervention group in 29.28% (based on a 40% 
risk reduction after the intervention), and m value of 1, the sample size for each arm will 
need to be 105 subjects, (total = 210) to detect a significant difference by the chi-square 
test. Assuming 40% of participants drop out or are lost to follow up, 294 women will be 
enrolled. 
Intervention 
The intervention will include a visit with a study nurse and/or a nutritionist in an 
outpatient setting once every 3 months for one year, beginning at enrollment. With each 
meeting, the patient will receive diet and physical activity counseling. The ultimate goal 
will be for the patient to lose 5% of her pre-pregnancy weight. All participants 
randomized to the control arm will receive the usual postnatal care, care similar to usual 
primary care including leaflets containing information of healthy diet and exercise habits.  
 The dietary intervention: The participants in the intervention arm will be 
encouraged to increase their intake of vegetables, legumes, fruits, berries, whole grains, 
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fiber, low-fat dairy, and vegetable fats. The goal will be to meet a specified diet 
modification that will allow the patient to lose weight. Diet modification goals include: 
saturated fat intake <10% of energy consumed, total fat intake 40% of energy consumed, 
carbohydrate intake 40% of energy consumed, protein intake 20% of energy consumed 
and fiber intake 20-30 g/day.30,51 During the first meeting, the study nurse and nutritionist 
will work with the patient to create a sample menu for 5 days (including 5 breakfasts, 5 
lunches, and 5 dinners). Counseling on all of the following 11 topics will be discussed 
during the meeting: snacks, sugar-sweetened beverages, vegetables, fruits and berries, 
low-fat cheese, cooking fat, spread fat, fast food, high-fiber, bread and cereal, fish, and 
low-fat milk. Specific caloric intake will not be recorded. However, because women who 
are breastfeeding have different caloric needs compared to those who are not, this will be 
discussed during nutrition counseling. Recommended energy intake for breastfeeding 
women in the first 6 months postpartum ranges from 2130-2730 kcal/day and 2200-2800 
kcal/day after 7 months of lactation.61 During the postpartum period, information on 
breastfeeding and infant nutrition will also be given. At each 3-month visit, a dietary 
journal will be collected and reviewed. This will be used as motivation for participants as 
well as data collection. Patients in the control group will also keep dietary journals, which 
will be collected at each 3-month visit. 
 The physical activity intervention: The goal of physical activity counseling will be 
to achieve 150 minutes of leisure time physical activity per week (e.g. 30 minutes of 
moderate intensity physical activity 5 times per week). During the study visits every three 
months, participants will work with study nurses to develop an exercise plan that can be 
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modified every three months as needed. Physical activity log books will be used as 
motivation and used for data collection. Patients will wear a pedometer and heart rate 
monitor during exercise that will be used to determine physical activity intensity. Patients 
in the control group will also keep physical activity journals, which will be collected at 
each 3-month visit. 
Study variables and measures 
Primary outcome: The primary outcome will be the incidence of GDM in the subsequent 
pregnancy after the index pregnancy. GDM in the subsequent pregnancy will be 
diagnosed on the IADPSG protocol as described in Table 4.33 
Table 4: IADPSG Recommendations for diagnosis of hyperglycemia in 
pregnancy 
 
At first visit, assign diagnosis of preexisting diabetes if any of the following are present: 
1) Fasting plasma glucose ≥ 126 mg/dL (≥6.99 mmol/L) 
2) Hb A1C ≥6.5% (≥48 mmol/mol) 
3) Random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) 
(confirmed by FPG or Hb A1C) 
At first visit, assign diagnosis of gestational diabetes if present: 
1) Fasting plasma glucose ≥92 mg/dL (≥5.11 mmol/L) and < 126 mg/dL (<6.99 mmol/L) 
At 24-28 weeks gestation, perform 75-g, 2-h OGTT. Assign diagnosis of gestational diabetes if 
one or more of the following plasma glucose values is met or exceeded: 
1) Fasting 92 mg/dL (5.11 mmol/L) 
2) 1 h 180 mg/dL (9.99 mmol/L) 
3) 2 h 153 mg/dL (8.49 mmol/L) 
Adapted from the International Association of Diabetes and Pregnancy Study Groups Consensus Panel33 and Coustan et al3 
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Secondary outcomes: Secondary outcomes include gestational weight gain and 
change in pre-pregnancy BMI units from the index pregnancy to the subsequent 
pregnancy, whether dietary and physical activity goals are met, and fasting plasma 
glucose concentrations taken at the visit every 3 months. Demographic data such as age, 
ethnicity, parity, length of the IPI, previous management of GDM (diet-treated, oral 
hypoglycemic agent, or insulin), socioeconomic status, and family history of diabetes, 
will also be collected to analyze confounding factors. Birth control method used during 
the IPI will also be recorded and adjusted for due to metabolic changes that occur as the 
result of hormonal birth control methods.  
Recruitment and enrollment 
Participants will be recruited either by their participating obstetrician at Boston Medical 
Center during their index pregnancy which has been complicated by GDM or through 
advertisements in the local media (newspapers and television) in Boston. Eligible women 
will meet with a study nurse and provider 6-weeks post-partum. The visit will include a 
detailed explanation of the study, informed consent, and completion of a medical 
questionnaire to determine eligibility based on inclusion/exclusion criteria. The patient 
will undergo OGTT and a physical exam will be performed. The women will then 
undergo informed consent and be enrolled.  
Incentives for participation include $30 cash upon enrollment and $10 at each 
visit with the study nurse. 
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Data collection 
At enrollment, the following data will be collected for intervention and control groups: 
blood pressure, heart rate, weight, height, BMI, waist and hip circumference, self-
reported pregnancy BMI (Kg/m2), treatment of GDM in index pregnancy (diet-treated, 
oral hypoglycemic agent, insulin), perinatal outcomes of the index pregnancy (birth 
weight and length, gestational age, sex of the infant, Apgar score, perinatal 
complications). 
 At each 3-month visit the following data will be collected for the intervention and 
control groups: physical exam findings (blood pressure, heart rate, respiratory rate, O2 
saturation), anthropometric measurements (weight, height, BMI, waist and hip 
circumference), food frequency questionnaire collected from diet logs kept by the 
subjects, diet index, and physical activity index. Diet index will be a composite of 
consumption of each of the following 11 categories of food discussed above scored from 
0-2 (2 is healthy, 0 is unhealthy): snacks, sugar-sweetened beverages, vegetables, fruits 
and berries, low-fat cheese, cooking fat, spread fat, fast food, high-fiber, bread and cereal, 
fish, and low-fat milk. Whether the subject met or did not meet the diet modification 
goals will be recorded. Physical activity will be recorded by number of minutes spent 
doing leisure time activity. Physical activity index will be a composite of number of 
minutes per week (0; <100, 1; 100-150, 2; 150-200; 3: >200) and intensity of exercise 
based on results of pedometer and heart rate monitor.  
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Data analysis 
The difference in incidence of recurrent GDM among the intervention and control groups 
will be analyzed for significance using a chi-square analysis. The secondary outcomes 
will be tested for significance using a t-test for continuous variables that are normally 
distributed, Mann-Whitney U test for continuous variables that are not normally 
distributed, or chi-square test for categorical variables. Multiple regression analysis will 
be used to adjust for confounding variables. The level of significance will be set at 
p=0.05. 
Timeline and resources 
During summer 2018, the study will be submitted to IRB for approval, providers and 
study nurses will be recruited and trained, and advertisements or brochures advertising 
participation in the study will be developed. Recruitment and enrollment will begin in fall 
2018. Participants will begin the study as they are enrolled. Enrollment will continue 
until sample size is reached (estimated one year of enrollment). After completion of 
enrollment, women will continue with the year-long intervention. Women who 
participated will be followed for a diagnosis of GDM in their second pregnancy. The 
timeline is outlined below in Table 5: 
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Table 5: Project timeline 
Summer 2018 
1) IRB submission and approval 
2) Recruitment of participating study sites, nurses, providers 
3) Development of participant recruitment tools: advertisements/brochures 
Fall 2018-Fall 2019 
1) Enroll subjects 
o Recruit women with current GDM 
o Set up 6-week post-partum appointment with eligible women 
o Sign consent forms 
2) Begin intervention 
o Begin intervention 
Fall 2019-Fall 2020 
1) Stop enrollment 
2) Continue intervention 
3) Begin follow-up period for women completing intervention 
o Follow for subsequent pregnancy 
o Record if GDM is diagnosed in subsequent pregnancy 
 
Project oversight, data collection, and data entry will all be completed by the 
primary investigator. Study nurses and nutritionists will see patients at each 3-month 
follow-up for vitals, physical exam, blood tests, and diet and exercise counseling 
(intervention only). Data analysis will be completed with the help of a statistician.  
 
Institutional Review Board 
This study will be submitted to review to the Boston University Medical Campus IRB for 
full review. This study is submitted for full review because an intervention will be 
applied to human subjects which does not fall within one of the 9 categories needed to 
qualify for expedited review.  
 
  
 32 
CONCLUSION 
Discussion 
GDM significantly impacts a woman’s life and carries a large health and economic 
burden. Although guidelines are established for screening, diagnosis, and management 
during a pregnancy complicated by GDM, post-partum follow up is lacking. A diagnosis 
of GDM has many long-term sequelae including risk of recurrent GDM, 
overweight/obesity, and development of T2DM. Therefore, follow-up post-partum after 
GDM is critical in preventing these consequences. While many studies have examined 
interventions that prevent T2DM, few studies have examined interventions that 
specifically prevent recurrent GDM. Prevention of recurrent GDM is important because a 
recurrent episode of GDM involves increased medical care during pregnancy, risk of 
adverse pregnancy outcomes, and elevated long-term maternal and fetal risk of obesity 
and T2DM.  
This study will examine a lifestyle intervention, which ultimately may reduce 
incidence of recurrent GDM. However, there are limitations, which must be highlighted. 
First, this study is relatively long (1-year follow-up) which may lead to a larger group of 
women lost to follow-up larger than expected. Secondly, recruitment may take longer 
than expected because women who have GDM in a current pregnancy must be planning 
to have a subsequent pregnancy and be willing to use one form of contraception in the 
interconception period to prevent pregnancy during the intervention period. Lastly, due to 
potential complications, burden of management, and risk of recurrence, the diagnosis of 
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GDM in the index pregnancy may affect a woman’s desire to have a second pregnancy. 
This may affect recruitment of participants.  
 If found to be effective, the findings of the study are generalizable as it only 
requires the participant to visit with a nurse or provider one time every three months. In 
general, the intervention is not difficult to implement from the provider’s perspective. 
However, lifestyle changes such as increased leisure time physical activity and healthy 
diet changes can be particularly difficult for mothers with a newborn as they can be time 
consuming. For this reason, if motivation is lacking, the intervention may not function 
with all mothers. Despite these obstacles, this intervention will give women the tools to 
begin a healthy lifestyle.  
Summary 
Management and prevention of GDM is incredibly important in ensuring a healthy 
pregnancy and preventing long-term health complications. As more Americans are 
affected by GDM and T2DM, it is becoming more important to manage risk factors for 
these diseases early. Because GDM and T2DM share similar risk factors, GDM is an 
early indicator for T2DM in the long term. This provides an ideal opportunity to target a 
patient’s risk factors and halt the diabetes disease course before any adverse health events 
take place. Although many studies have focused on the prevention of T2DM after GDM, 
there is literature lacking on targeting the IPI to prevent recurrent GDM.  
Prevention of recurrent GDM is important for many reasons. By preventing a 
recurrent episode of GDM, a patient’s risk of short-term consequences from GDM is 
reduced. Additionally, recurrent GDM increases a patient’s risk of developing T2DM 
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while a subsequent pregnancy not complicated by GDM may be protective against 
T2DM. For this reason, an intervention that can prevent a recurrent episode of GDM may 
provide the perfect opportunity to alter the diabetes disease course.  
Clinical and/or public health significance 
The public health implications of GDM are immense and prevention will lead to 
improved maternal and fetal outcomes. T2DM, a major sequela of GDM, is emerging as 
a leading cause of death and disability in the United States. People with T2DM are at 
increased risk for developing renal, cardiovascular, and retinal diseases which poses a 
significant economic burden, $91.8 billion per year in the United States.6 Because many 
women with a history of GDM develop T2DM, preventing GDM may decrease incidence 
of T2DM, relieving its public health burden.  
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